BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2000

View Archived Issues

Boehringer Ingelheim seeks approval for combination hypertension treatments

Read More

3M Drug Delivery Systems Division provides new pain management platform

Read More

Aptosyn/Xeloda combination to be tested in breast and colorectal cancers

Read More

Cellegy to commence phase II trial of Anogesic as hemorrhoid treatment

Read More

PathoGenesis establishes Paris-based company to distribute TOBI in France

Read More

Clinical trials of Alzheimer's disease diagnostic test commence

Read More

Magainin begins phase II trial of squalamine in ovarian cancer

Read More

IDEC-152 enters clinical trials for treatment of allergic asthma

Read More

Enrollment in phase I study of Avant's CETP vaccine now complete

Read More

Antizol granted conditional priority review by Canadian authorities

Read More

Enzo achieves successful transduction of human cells using novel vector

Read More

New Sumitomo compounds inhibit cytokine and IgE production

Read More

Taisho synthesizes new series for CRF-related disorders

Read More

More news from CROI: AIDSVAX clinical results presented

Read More

Antiinfluenza sialic acid derivatives emerge from R&D at RIKEN

Read More

Gastric antisecretory agents from KRICT superior to omeprazole in vitro and in vivo

Read More

Nonpeptide inhibitors of VLA-4-dependent cell adhesion in the Pfizer pipeline

Read More

Group of selective SK channel blockers in early development at NeuroSearch

Read More

Antisense oligonucleotides targeting IL-15 designed at Hisamitsu

Read More

Antiasthmatic agent ME-3301 in clinical trials in Europe

Read More

North American Vaccine reports Hib vaccine results to FDA advisory panel

Read More

United Biomedical reports progress toward the development of a potential AIDS vaccine

Read More

Enbrel receives E.U. approval as treatment for rheumatoid arthritis

Read More

Roche announces limitations on availability of FUDR

Read More

Chinese investigators design novel antitumor agents

Read More

U.S. and Scottish scientists discover novel CCR3 antagonist that inhibits eosinophil migration

Read More

Termination of AHP-Warner-Lambert merger proposal confirmed

Read More

Methods of wound healing using amphipathic peptides from Demegen

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing